Testosterone (TS) replacement therapy for men with hypogonadism has traditionally involved the administration of a long-acting TS ester (TS enanthate or TS cypionate) or trandermal preparations (1,2). TS transdermal drug delivery system has especially been well accepted because of various advantages including the following: 1) avoidance of ifrst pass metabolism; 2) reduction of side effects due to decrease in plasma levels; 30 improvmeent of therapy due to maintenance of plasma levels; 4) ease of discontinuing the administration; 5) effectiveness for drugs with shrot half-lives; 6) avoidance of side effects in the GI tract. In this study, new matrix-type transdermal systems of TS were formulated using either Duro-Tak~direct R 87-2510 (National Starch, USA) or As-923 (Il-yang Pharmaceutical Co., Korea) as adhesives. The effects of surfactants and absorption ehancers were sytematically investigated in in vitro and in vivo studies in the rat model.
展开▼
